中华眼外伤职业眼病杂志
中華眼外傷職業眼病雜誌
중화안외상직업안병잡지
CHINESE JOURNAL OF OCULAR TRAUMA AND OCCUPATIONAL EYE DISEASE
2015年
7期
492-496
,共5页
糖尿病视网膜病变,增生性%雷珠单抗%玻璃体内注药%玻璃体积血%玻璃体切除术
糖尿病視網膜病變,增生性%雷珠單抗%玻璃體內註藥%玻璃體積血%玻璃體切除術
당뇨병시망막병변,증생성%뢰주단항%파리체내주약%파리체적혈%파리체절제술
Diabetic retinopathy,proliferative%Ranibizumab/Lucentis%Injections,intravitreal%Vitreous Hemorrhage%Pars plana vitrectomy
目的：观察玻璃体内注射雷珠单抗在治疗轻中型增生性糖尿病视网膜病变玻璃体积血中的效果。方法轻中型增生性糖尿病视网膜病变玻璃体积血患者30例(39只眼)接受雷珠单抗注射作为注药组,17例(24只眼)不愿注射雷珠单抗作为对照组。观察记录注药后玻璃体积血吸收情况,及后续治疗措施和效果。随诊时间6~18个月。结果雷珠单抗注射后6个月,避免玻璃体切除术共8只眼,注药组8只眼(20.51%)与对照组0只眼比较,差异有统计学意义(矫正χ2=3.9406, P=0.0471)；行玻璃体切除术共55只眼,注药组31只眼、9只眼玻璃体腔硅油填充(29.03%),对照组24只眼、17只眼玻璃体腔硅油填充(70.83%),硅油填充率比较差异有统计学意义(χ2=9.4829,P=0.0021)。结论雷珠单抗在轻中型增生性糖尿病视网膜病变玻璃体积血的治疗中,不仅能使玻璃体切除手术操作变得简单易行,而且甚至可以避免部分患者的玻璃体切除手术。
目的：觀察玻璃體內註射雷珠單抗在治療輕中型增生性糖尿病視網膜病變玻璃體積血中的效果。方法輕中型增生性糖尿病視網膜病變玻璃體積血患者30例(39隻眼)接受雷珠單抗註射作為註藥組,17例(24隻眼)不願註射雷珠單抗作為對照組。觀察記錄註藥後玻璃體積血吸收情況,及後續治療措施和效果。隨診時間6~18箇月。結果雷珠單抗註射後6箇月,避免玻璃體切除術共8隻眼,註藥組8隻眼(20.51%)與對照組0隻眼比較,差異有統計學意義(矯正χ2=3.9406, P=0.0471)；行玻璃體切除術共55隻眼,註藥組31隻眼、9隻眼玻璃體腔硅油填充(29.03%),對照組24隻眼、17隻眼玻璃體腔硅油填充(70.83%),硅油填充率比較差異有統計學意義(χ2=9.4829,P=0.0021)。結論雷珠單抗在輕中型增生性糖尿病視網膜病變玻璃體積血的治療中,不僅能使玻璃體切除手術操作變得簡單易行,而且甚至可以避免部分患者的玻璃體切除手術。
목적：관찰파리체내주사뢰주단항재치료경중형증생성당뇨병시망막병변파리체적혈중적효과。방법경중형증생성당뇨병시망막병변파리체적혈환자30례(39지안)접수뢰주단항주사작위주약조,17례(24지안)불원주사뢰주단항작위대조조。관찰기록주약후파리체적혈흡수정황,급후속치료조시화효과。수진시간6~18개월。결과뢰주단항주사후6개월,피면파리체절제술공8지안,주약조8지안(20.51%)여대조조0지안비교,차이유통계학의의(교정χ2=3.9406, P=0.0471)；행파리체절제술공55지안,주약조31지안、9지안파리체강규유전충(29.03%),대조조24지안、17지안파리체강규유전충(70.83%),규유전충솔비교차이유통계학의의(χ2=9.4829,P=0.0021)。결론뢰주단항재경중형증생성당뇨병시망막병변파리체적혈적치료중,불부능사파리체절제수술조작변득간단역행,이차심지가이피면부분환자적파리체절제수술。
Objective To study the effect of intravitreal injection of Ranibizumab for vitreous hemorrhage in the non-severe proliferative diabetic retinopathy (N-SPDR). Methods Thirty-nine eyes of 30 N-SPDR patients with vitreous hemorrhage were given intravitreal Ranibizumab injection as the injection group. Twenty-four eyes of 17 N-SPDR patients with vitreous hemorrhage who refused intravitreal Ranibizumab injection were enrolled as the control group. The course of absorption of vitreous hemorrhage, the measures and effects of the subsequent treatment were recorded. The follow-up time was 6-18 months. Results Six months after intravitreal Ranibizumab injection, the total number of the eyes avoiding vitrectomy was 8, in the injection group 8 eyes ( 20. 51%) compared with 0 in the control group, the difference was statistically significant (correct χ2 =3. 9406, P =0. 0471). The total number of the eyes receiving vitrectomy was 55, in the injection group 9 eyes of 31 (29. 03%) were filled with silicone oil, compared with 17 eyes of 24 (70. 83%) filling with silicone oil in the control group, the difference was statistically significant (χ2 =9. 4829, P=0. 0021). Conclusion Intravitreous injection of Ranibizumab for the N-SPDR patients with vitreous hemorrhage can not only reduce the possibility of vitrectomy for some patients, but also reduce the difficulties and complications of the vitrectomy for others.
